SUPERNUS PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $2.5B
- as of Sep 30, 2026
- Shares Outstanding
- 58.1M
- Free Float
- 80.7%
Income Statement
- Revenue
- $719.0M
- Operating Income
- -$62.3M
- Net Income
- -$38.5M
- EBITDA
- $29.3M
- Revenue Growth, 3Y
- 2.5%
- FCF Margin, 3Y Avg
- 16.8%
- FCF Margin, Worst Year
- 6.4%
Cash Flow
- Free Cash Flow
- $46.0M
- FCF Yield
- 1.8%
- Owner FCF Yield
- 0.5%
Balance Sheet
- Cash & Equivalents
- $128.4M
Returns & Capital
- SBC, 3Y Avg
- $29.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $719.0M | $46.0M | 6.4% |
| FY2024 | $661.8M | $171.2M | 25.9% |
| FY2023 | $607.5M | $110.5M | 18.2% |
| FY2022 | $667.2M | $116.4M | 17.4% |
| FY2021 | $579.8M | — | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 2, 2026
Deals
Indivior Completes All-Stock Merger With Supernus
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Supernus Pharmaceuticals to Merge With Indivior Pharmaceuticals in All-Stock Deal
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger
Indivior Completes All-Stock Merger With Supernus
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Supernus Pharmaceuticals to Merge With Indivior Pharmaceuticals in All-Stock Deal
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger